admin 
For more than five decades, Alan Schwartz has been helping innovators navigate one of the most challenging environments in business: regulatory compliance. While many entrepreneurs view regulation as a barrier to growth, Schwartz has spent his career proving that it can be a catalyst for innovation, trust, and long-term success.
As Founder and President of mdi Consultants, Inc., a leading regulatory and quality assurance consulting firm based in Great Neck, New York, Schwartz has guided thousands of medical devices, pharmaceutical, biotechnology, and food companies through complex regulatory pathways. His work has helped organizations transform groundbreaking ideas into market-ready products while meeting the rigorous standards required to protect public health.
What sets Schwartz apart is not simply his technical expertise, but his ability to bridge two worlds that are often perceived as adversaries: government regulators and commercial innovators. Throughout his career, he has advocated for a philosophy rooted in transparency, accountability, and proactive problem-solving—principles that have become the foundation of mdi Consultants’ enduring success.
From FDA Investigator to Industry Advisor
Schwartz’s professional journey began in 1972 during a challenging economic climate. Armed with a biology degree and searching for career opportunities during a recession, he accepted a position as a field investigator with the U.S. Food and Drug Administration (FDA). What initially seemed like a practical career decision soon evolved into a lifelong passion.
During his time with the FDA, Schwartz conducted inspections, evaluated manufacturing processes, and assessed quality systems across a wide range of industries. The experience provided him with a rare inside view of how regulations are interpreted, enforced, and applied in real-world settings.
His rapid advancement within the agency reflected both his analytical mindset and leadership capabilities. Within just a few years, he rose to a supervisory role, overseeing investigations and managing teams responsible for ensuring compliance with federal regulations.
Yet the experience also revealed a recurring challenge. Many innovative companies, particularly smaller organizations, struggled not because they lacked quality products, but because they lacked the regulatory knowledge needed to communicate effectively with government agencies.
Recognizing this gap, Schwartz made a bold entrepreneurial decision. In 1978, he left the security of federal service to establish his own consulting practice—one dedicated to helping organizations understand regulatory expectations and navigate them successfully.
Transforming Compliance into Competitive Advantage
The timing could not have been more significant. The late 1970s marked a period of major regulatory transformation following the Medical Device Amendments of 1976 and the introduction of Good Manufacturing Practices (GMPs) for medical devices.
As businesses adapted to new compliance requirements, Schwartz positioned himself as a trusted advisor capable of translating complex regulations into practical business strategies.
Over time, he developed a core philosophy that continues to guide both his leadership and his firm’s approach:
“You learn far more from examining the companies that face severe regulatory hurdles than from those that smoothly cruise through compliance. The ultimate differentiator is always management’s willingness to confront an operational problem immediately, transparently, and with data-backed accountability.”
Rather than encouraging clients to view regulators as obstacles, Schwartz advocated for collaboration, preparation, and openness. This perspective helped clients build stronger quality systems, avoid costly setbacks, and achieve more efficient regulatory outcomes.
Reinventing the Consulting Model
As mdi Consultants expanded, Schwartz identified another opportunity for innovation—not within regulation itself, but within consulting.
Traditional advisory services often relied on hourly billing structures that created uncertainty for clients and made budgeting difficult, particularly for emerging companies with limited resources.
In response, Schwartz introduced a fixed-price consulting model that would become a defining feature of the firm’s value proposition. Clients received a clear scope of work and a predetermined cost, allowing them to plan with confidence while eliminating concerns about escalating fees.
The approach also challenged mdi to become more efficient, disciplined, and results-oriented. By assuming greater responsibility for execution, the firm strengthened client relationships and differentiated itself in a highly competitive marketplace.
Solving the Industry’s Toughest Challenges
Among the many achievements that have defined Schwartz’s career, some of the most notable involve helping clients overcome seemingly insurmountable regulatory obstacles.
One particularly significant case involved a highly advanced stereotactic radiation therapy system that had received a Non-Substantial Equivalence (NSE) determination from the FDA—a decision that typically represents a major setback for a product’s commercial future.
Rather than accepting the outcome, Schwartz and his team conducted a comprehensive reassessment of the submission strategy. Through extensive technical analysis, additional supporting evidence, and direct engagement with regulators, they successfully secured a reversal of the decision.
The accomplishment demonstrated not only regulatory expertise but also the importance of persistence, preparation, and strategic thinking. Similar successes have helped establish mdi Consultants as a trusted partner for organizations facing complex regulatory challenges.
Preparing Clients for the Future
Even after more than 50 years in the industry, Schwartz remains focused on emerging trends shaping the future of healthcare and medical technology.
He has been an early advocate for understanding the regulatory implications of artificial intelligence, digital health technologies, and connected medical devices. Long before AI became a mainstream topic, mdi Consultants assisted with regulatory submissions involving intelligent diagnostic technologies designed to support clinical decision-making.
Today, cybersecurity has become an equally critical area of focus. As healthcare systems become increasingly interconnected, manufacturers must address growing concerns surrounding data security, software integrity, and patient protection.
Under Schwartz’s leadership, mdi continues to expand its capabilities to help clients navigate evolving requirements while maintaining compliance in a rapidly changing technological landscape.
A Legacy Built on Trust
Reflecting on his career, Schwartz views regulatory compliance not as a collection of rules, but as a framework for building trust between innovators, regulators, healthcare providers, and patients.
His leadership has guided thousands of organizations through complex regulatory environments, supported the commercialization of life-changing technologies, and helped shape industry best practices across multiple sectors.
More importantly, he has demonstrated that sustainable success is built on transparency, integrity, and a willingness to embrace accountability.
As healthcare innovation continues to accelerate, Alan Schwartz’s influence remains a powerful reminder that progress and compliance are not competing priorities. When approached strategically, they become partners in advancing safer, more effective solutions for people around the world.
Magazine 
